-
Featured Authors
Business of Biotech
Archive
- June 2013 (2)
- April 2013 (1)
- February 2013 (2)
- January 2013 (1)
- October 2012 (1)
- September 2012 (3)
- August 2012 (1)
- January 2012 (3)
- December 2011 (2)
- October 2011 (3)
- August 2011 (3)
- July 2011 (2)
- June 2011 (12)
- April 2011 (2)
- January 2010 (1)
- November 2009 (1)
- October 2009 (47)
- September 2009 (37)
- August 2009 (1)
- June 2008 (3)
- May 2008 (2)
- April 2008 (1)
- February 2008 (6)
Category Archives: Business of Biotech
2008 BIO International Convention Show Daily
The Scientist, our trade publication partner for the daily newsletter at the convention, has extended their editorial submission deadline to April 30th. To submit newsworthy content, go to www.the-scientist.com/bio/index/ . Submit something today!
Record number of institutional investors at CEO
The final numbers are in and we have good reason to celebrate (perhaps we should get a three-day weekend?!) - there were a record number of institutional investors at the CEO & Investor Conference, 1,050 in total. Most of the more than 200 company presentations were full rooms, since in total we had more than 2000 participants. And obviously a lot of dealmaking and potential dealmaking was in the works with more than 1400 one-on-one meetings.
Duck taped to the side of a train
Despite a delayed train, I got home at 11:30 last night, not too bad considering how bad it could have been! At least the thirty minute delay allowed me to hang out with Mary from Amtrak who repeatedly got requests from folks trying to move up their reservations and she had the pleasure of turning them away one after another since all the trains were filled to the brim. At least she offered them all Read More >
From Fuel to Food to Fashion
Industrial biotech does it all. The Third Wave in biotech is looking bright for the future. Industrial biotech represents the confluence of market demand and the potential for market solution, according to David Berry, MD, PhD of Flagship Ventures – one of the panel speakers. Synthetic biotechnology, for one, is enabling the next generation in biofuels, while companies like Mascoma are commercializing cellulosic ethanol. The future vision for industrial biotech is to have a significant and Read More >
Mind the Gap: Pharma Chasing Biotech Assets
Validation with big pharma – is it still necessary? Depends on who you talk to. This was one of several questions posed to panelists at today’s business roundtable session. Arguments can be made on both sides, but one thing is for certain, the life sciences financing community has become much more sophisticated in recent years. And biotech and pharma companies have become more sophisticated in doing deals because they have a lot more experience to Read More >
